SIGNABLOK, INC.

Company Information
Address 61 FRANK ST, APT 36
WORCESTER, MA, 01604-1000

http://www.signablok.com

Information

DUNS: 962285263

# of Employees: 2


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer

    Amount: $224,672.00

    Project Summary Abstract Carcinoma of the pancreas or pancreatic cancer PC is the fourth leading cause of cancer related death in the United States According to the American Cancer Society ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Treatment of alcoholic liver disease with novel targeted inhibitors

    Amount: $223,443.00

    DESCRIPTION provided by applicant Alcoholic liver disease ALD affects millions of people globally and often leads to fibrosis and cirrhosis With a total of deaths in of which we ...

    SBIRPhase I2016Department of Health and Human Services
  3. Development of novel targeted agents in pancreatic cancer

    Amount: $219,937.00

    DESCRIPTION provided by applicant Carcinoma of the pancreas or pancreatic cancer PC is the fourth leading cause of cancer related death in the United States According to the American Cancer So ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  4. Novel mechanism-based targeted approach to rheumatoid arthritis

    Amount: $223,013.00

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes chronic inflammation of the joints. RA affects about 1.5 million Americans and c ...

    SBIRPhase I2014Department of Health and Human Services
  5. Multifunctional nanoformulations for diagnostic imaging of atherosclerosis

    Amount: $1,342,812.00

    DESCRIPTION provided by applicant Despite advances in cardiovascular care atherosclerosis remains the leading cause of mortality in the United States and worldwide A vast majority of cardiovascul ...

    SBIRPhase II2014Department of Health and Human Services National Institutes of Health
  6. Development of novel targeted agents in lung cancer

    Amount: $221,738.00

    DESCRIPTION (provided by applicant): Non-small cell lung cancer (NSCLC) affects over 222,000 Americans annually. Despite advances in therapy, the 5-year survival rate is as low as 15%. Current treatm ...

    SBIRPhase I2012Department of Health and Human Services
  7. Multifunctional nanoformulations for diagnostic imaging of atherosclerosis

    Amount: $221,829.00

    DESCRIPTION (provided by applicant): Despite advances in cardiovascular care, atherosclerosis remains the leading cause of mortality in the United States and worldwide. A vast majority of cardiovascul ...

    SBIRPhase I2012Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government